Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Halozyme Therapeutics

- PMLiVE

Aduro pancreatic cancer vaccine trial disappoints

Immunotherapy combination fails to improve overall survival over existing treatments

Celgene building

Wales backs NHS use of Abraxane despite NICE rejection

Overrules UK decision and will maintain access to Celgene’s pancreatic cancer drug

- PMLiVE

Incyte abandons solid tumour programme for Jakafi

Drug discontinued after failure to show efficacy in trials

- PMLiVE

FDA approves Merrimack’s pancreatic cancer drug

Onivyde improves overall survival rates

FDA teams up with PatientsLikeMe for patient data project

Will explore its potential to inform the regulator'approach to risk assessment

- PMLiVE

Merck KGaA, Threshold gain FDA fast-track review

Industry partners hope their new cancer drug will be approved by the end of the year

- PMLiVE

Baxter and Merrimack file pancreatic cancer drug in EU

MM-398 is thought to help direct the active drug into tumours

- PMLiVE

Indian generics firm GVK set to be hit with European sales ban

EU regulator raises concerns on conduct of drug studies in India

- PMLiVE

NICE rejects pancreatic cancer regimen over cost concerns

Charity says draft decision to deny Abraxane/Gemzar combo is a ‘backwards step’ for the NHS pricing body

- PMLiVE

Ranbaxy hit with EU import ban on antibiotic

Indian generics firm’s plant ruled in breach of manufacturing rules

- PMLiVE

Italy investigates Novartis vaccine after death toll reaches 13

Firms insist on the Fluad's safety, with 65 million doses given in the last 17 years

- PMLiVE

FDA adds rare brain infection link to Tecfidera labelling

Biogen Idec’s MS drug gets safety warning

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links